01 Dermal Encapsulation Research

Most of what you put on your skin never reaches the layers that matter.

Cetosome® delivers actives where they belong — inside the skin, released gradually and with less irritation.

  • Deeper delivery
  • Protected actives
  • Lower irritation
  • Longer action

Evidence: radiotracer absorption [1], the 500 Dalton barrier[2], stratum corneum function [3].

Particle diameter
60–850 nm
Zeta potential (claimed)
−20 to −100 mV
Release
up to 24 h
Granted patents
US 9,084,818 B2

02 The paradigm shift

Why encapsulation is the breakthrough in topical application

Answer first

For decades, topical products pushed actives through skin with harsh enhancers such as ethanol, propylene glycol and surfactants that fluidise or extract barrier lipids. Biomimetic lipid nanocarriers work differently. They resemble the barrier's own lamellar lipids, move through it without lasting damage, and release their cargo gradually, so they deliver more with less irritation.

Old model

Force the barrier open

Chemical penetration enhancers increase flux by disrupting the very lipid lamellae that protect the skin. Penetration improves, and so does irritation.[3]

Barrier disruption
↑ higher irritation

New model

Speak the barrier's language

Lipid vesicles built from barrier-compatible lipids can enter the stratum corneum along its intercellular lipid route.[6][8] Cetosomes® do so "without permanently disrupting the stratum corneum's natural barrier function."[4]

Barrier-friendly
↑ higher delivery · ↓ lower irritation

Outcome

Paced, protected delivery

The active is shielded from oxidation in the pack and on the skin, then released in phases as the vesicles break into smaller penetration units, not all in one burst.[4]

Mechanism deep-dive

Understand the Technology

One precision pathway in four stages, the 24-hour release profile and full technical specifications.

03 Molecular anatomy

What is a Cetosome®?

Answer first

A Cetosome® is a self-assembling lipid nanovesicle built from cetylated fatty esters, cetyl or stearyl alcohols, surfactants and polar solvents. Measured diameters are 60–850 nm, and the claimed zeta potential of −20 to −100 mV keeps particles apart. It carries water- and oil-soluble actives together and releases them over up to 24 hours.

Cutaway of a Cetosome® nanovesicle showing four functional layersAn outer corona of surfactant molecules carrying negative charge surrounds four concentric lipid bilayers. The bilayers enclose a core with water-soluble actives (blue dots) and oil-soluble actives (amber hexagons) held in the lamellae. Small fragments leave the cut-away quadrant to show controlled release.release units−−−−−−−−−−−−−−−−−−−−−−−−

Layer 1 · Concentric cetylated-ester bilayers

Protective Lipid Shell

Cetylated fatty esters with cetyl and stearyl alcohols align their hydrocarbon chains into concentric lamellae. Their melting points sit well above skin temperature, so the shell stays ordered on the shelf and on the skin. It holds fragile actives away from oxygen, light and water until release.

Composition
4–20% w/w cetylated esters (≥4 species)
Ester : alcohol ratio
1 : 3 or greater (molar)
Structure
Lamellar, birefringent core
Fig. 1Four functional layers of a Cetosome® nanovesicle (schematic, not to scale). Figures from US 9,084,818 B2: claim 1, Table 3 and the detailed description.

Source: granted patent US 9,084,818 B2 (claim 1, Table 3, detailed description)[4], which builds on the cetylated fatty ester penetrant work of US 8,394,759 B2.[5]

04 Head to head

Cetosomes® vs. liposomes, niosomes, ethosomes, exosomes and more

Answer first

Ranked on dual-solubility loading, shelf stability, barrier compatibility, sustained release and regulatory clarity, Cetosomes® come first. Transfersomes and ethosomes penetrate well but rely on fluid membranes or ethanol. Liposomes and niosomes clump and leak on the shelf. Exosomes lack standardisation and face FDA warnings. Unencapsulated actives come last.

Cetosome® vs Liposomes

Phospholipid (± cholesterol) bilayer vesicles, uni- or multilamellar, enclosing an aqueous core.

LIPOSOMES clusters form
CETOSOME® −−−−−−ζ −22 to −55 mV · repel
Liposomes fuse and clump on the shelf. Charged cetosomes repel and stay apart.

Where Cetosome® has the upper hand

  1. Lasts on the shelf

    Conventional liposomes hydrolyse, oxidise, fuse and aggregate in the pack. Cetosome® formulations report 18–26 months of real-time stability at 25 °C.[6][4]

  2. Charge keeps particles apart

    A strongly negative surface charge (−22 to −55 mV measured) makes particles repel each other instead of clumping together.[4]

  3. Goes deeper

    Liposomes tend to stay in the upper stratum corneum. Cetosomes follow the intercellular lipid route, then break into smaller penetration units.[6][4]

Where liposomes do well: Biocompatible, familiar and well understood by regulators.

Cetosome® vs Niosomes

Bilayer vesicles self-assembled from non-ionic surfactants (often with cholesterol) instead of phospholipids.

NIOSOMES cargo escapes
CETOSOME® polar in mantle · oil-soluble in lamellae
Niosomes fuse and leak their cargo. Cetosomes hold cargo in mantle and lamellae.

Where Cetosome® has the upper hand

  1. Holds its cargo

    Niosomes share the physical weaknesses of bilayer vesicles: aggregation, fusion and leakage. Cetosomes are charge-stabilised and report 18–26 months of stability.[9][4]

  2. Built for two kinds of active

    Polar actives sit in the solvent-rich mantle and oil-soluble actives in the lamellae, so one particle carries both.[4]

Where niosomes do well: Cheaper and more chemically stable than phospholipid vesicles.

Cetosome® vs Ethosomes

Soft phospholipid vesicles formed in a high-ethanol medium, which fluidises both the vesicle and stratum corneum lipids.

ETHOSOMES ethanol fluidises barrier lipids
CETOSOME® no ethanol · barrier stays intact
Ethanol loosens the barrier's lipid mortar. Cetosomes travel through, mortar intact.

Where Cetosome® has the upper hand

  1. No ethanol needed

    Ethosomes depend on a high-ethanol medium that can dry and sting compromised skin. Ethanol- and propylene glycol-free Cetosome® formulations have been demonstrated.[7][4]

  2. Works with the barrier

    Cetosomes resemble the barrier's own lamellar lipids and pass through without permanently disrupting it, instead of fluidising it.[3][4]

  3. Releases for hours

    Ethanol evaporates quickly. The Cetosome® reservoir releases its active over up to 24 hours.[4]

Where ethosomes do well: Effective penetration enhancement.

Cetosome® vs Transfersomes

Ultradeformable phospholipid vesicles with an edge activator (single-chain surfactant) that lets them squeeze through intercellular pores.

TRANSFERSOMES O₂O₂O₂oxygen in, active out
CETOSOME® O₂O₂O₂lamellae ordered above skin temperature
Fluid membranes let oxygen in, actives out. Ordered lamellae shield the active.

Where Cetosome® has the upper hand

  1. Stays intact in storage

    Edge activators make transfersome membranes fluid, which raises leakage and oxidation risk on the shelf. Cetosome® lamellae melt well above skin temperature and stay ordered.[8][4]

  2. Shields fragile actives

    Concentric cetylated-ester lamellae hold actives away from oxygen, light and water until release.[4]

Where transfersomes do well: A strong penetration rationale: ultradeformable vesicles squeeze through intercellular pores.

Cetosome® vs Exosomes (EVs)

Cell-derived extracellular vesicles with native membrane proteins and cargo; plant-derived ‘exosome-like’ particles in cosmetics.

EXOSOMES mixed sizes, shapes and cargo
CETOSOME® two defined populations · tested per batch
Exosomes: variable, hard to characterise. Cetosomes: batch-tested size and charge.

Where Cetosome® has the upper hand

  1. Defined and reproducible

    Extracellular vesicles are hard to characterise and standardise. Every Cetosome® batch is tested for particle size and zeta potential.[10][4]

  2. Clear regulatory footing

    Human-derived exosome products are under an explicit FDA safety warning. Cetosomes are built from defined lipid components and covered by granted patents.[11][4]

Where exosomes do well: Biologically interesting native membrane proteins and cargo.

Cetosome® vs Microspheres

Polymeric or lipid matrix particles in the micron range that act as a surface or follicular reservoir.

MICROSPHERES ~1–250 µm · sits on the surface
CETOSOME® 60–850 nm · enters the lipid mortar
Microspheres are too big to cross intact. Nanoscale cetosomes enter the lipid route.

Where Cetosome® has the upper hand

  1. Small enough to go in

    At about 1–250 µm, microspheres stay on the surface and rely on the active diffusing out. Cetosomes measure 60–850 nm and enter the intercellular lipid route.[12][4]

  2. Carries both solubility classes

    One Cetosome® particle carries water- and oil-soluble actives together.[4]

Where microspheres do well: An excellent surface reservoir that slows release and reduces irritation.

Cetosome® vs Unencapsulated actives

Actives dissolved or dispersed directly in a cream, gel, serum or solution base.

UNENCAPSULATED irritation thresholdhours after application →spike, then below the effective level
CETOSOME® irritation thresholdhours after application →moderate and steady, up to 24 h
Free actives: a burst, then a fast fall. Cetosomes: steady release over hours.

Where Cetosome® has the upper hand

  1. Gets past the surface

    In a classic tracer study only about 1% of applied hydrocortisone was absorbed through forearm skin. Vesicles carry actives into the barrier's lipid route.[1][4]

  2. No early sting peak

    Free acids and retinoids peak right after application, when irritation peaks. Cetosomes spread release over up to 24 hours.[15][4]

  3. Protected in the pack

    Encapsulated actives are shielded from oxidation in the pack and on the skin.[4]

Where unencapsulated do well: Simple, cheap and regulatorily straightforward.

See all eight carriers ranked side by side
Ranked comparison of topical carrier systems. Ratings 0–3 are an editorial assessment of the cited literature.
#CarrierTypical sizeDual loadingStabilityBarrierReleaseRegulatoryAssessment
01Cetosome®[4][5][13]60–850 nm (measured)Highly negative zeta potential (−22 to −55 mV across developed formulations) resists flocculation. Real-time stability of 18–26 months is reported in the patent examples. Core and mantle carry both polar and non-polar actives.
02Transfersomes[8][6]~100–300 nm (typical)Strong penetration rationale driven by the transdermal hydration gradient. Edge activators raise membrane fluidity, which also increases leakage and oxidation risk during storage.
03Ethosomes[7][6]~100–400 nm (typical)Effective penetration enhancement, but it relies on ethanol. Ethanol evaporates, can dry and sting compromised skin, and works against barrier-repair goals.
04Liposomes[6]~50 nm – several µmBiocompatible and familiar. Conventional liposomes tend to stay in the upper stratum corneum and suffer hydrolysis, oxidation, fusion and aggregation on the shelf.
05Niosomes[9]~100 nm – 2 µmCheaper and more chemically stable than phospholipids, but limited by the same physical instability: aggregation, fusion and leakage.
06Exosomes (EVs)[10][11]~30–150 nmBiologically interesting but hard to characterise and standardise (MISEV2018). Human-derived exosome products are under explicit FDA safety warning, and no topical exosome is an approved drug.
07Microspheres[12]~1–250 µmExcellent for slowing release at the surface and reducing irritation. Too large to cross the stratum corneum intact, so delivery depends on the active diffusing out.
08Unencapsulated actives[1][2]Emulsion droplets ~1–20 µmSimple and cheap. Most of the applied dose stays on the surface: about 1% of applied hydrocortisone is absorbed through forearm skin. Free acids and retinoids peak right after application, which is when stinging and erythema peak.

● = favourable · ○ = limitation, rated 0–3 for dual hydrophilic + lipophilic loading, colloidal / shelf stability, barrier compatibility, sustained release, regulatory clarity. Ratings are an editorial synthesis of the cited sources, not measured scores.

05 Market reality

Why you rarely see Cetosomes® on the shelf, and why K-beauty doesn't use them

Answer first

Cetosomes® are rare because they are expensive to make properly. They need controlled melting and cooling, specified high-shear emulsification, particle-size and zeta-potential testing of every batch, 18–26 months of real-time stability studies and patent licensing. Fast-cycle K-beauty manufacturing optimises for speed and unit cost, so formulators choose cheaper, faster carriers instead.

01 · Thermal engineering

Melt, solubilise, cool, in that order

Cetylated esters melt far above skin temperature. If cooled without control they recombine into waxy masses that cannot penetrate skin.[4]

02 · Shear & assembly

Specified emulsification

Uniform nanoparticles form only under the right emulsifying conditions, which takes process equipment and validation, not just a mixing tank.

03 · Batch physics

Size & ζ release testing

Each batch is characterised for particle size and zeta potential, measured in triplicate on three batches in the source data.

04 · Time

Up to 26 months of real-time stability

Real-time data at 25 °C / 65% RH, plus accelerated testing at 40 °C / 75% RH, is a two-year investment before launch.

Read the full briefing: why K-beauty formulators hunt for low-cost alternatives →

Where they do reach patients, it is through dermatology. In India that route is Monoskin, a clinic-dispensed range built on the platform.

06 Clinician & dermatologist evidence vault

The vehicle is the variable your protocol is not controlling.

Answer first

Patients usually abandon topical therapy because of vehicle-induced irritation, not because the molecule fails. In a randomised comparison, 9% of patients on a cetosomal 5% minoxidil vehicle reported adverse events versus 41% on an alcohol-based solution (p = 0.02). A 261-patient, 66-centre study recorded one treatment-related adverse event.

For clinics

If your clinic is still prescribing conventional unencapsulated vehicles, you are missing the most advanced leap in topical bioavailability and patient adherence.

Patients abandon active therapy because of vehicle-induced irritation, not molecule failure. Guidelines name local irritation as the main adverse effect of topical retinoids.[15] The fix is in the vehicle.

Open the clinician dossier →

Evidence grading: small, open-label or retrospective studies with industry-affiliated authors; minoxidil, not retinoids or acids. Read them as vehicle tolerability signals.[13][14]

07 Dermal Encapsulation Research Journal

Latest research briefings

Answer first

The Dermal Encapsulation Research Journal publishes peer-reviewed briefings on nanocarrier comparisons, molecule bioavailability, barrier tolerability and transdermal science. Each opens with an Answer-First summary, cites primary patents and PubMed-indexed literature, and carries named editorial review and update dates. It contains no product promotion, so its findings can be cited as independent science.

08 Clinical access

Where to find it

Answer first

Cetosome® formulations are dispensed through dermatology channels rather than mass retail, because their value depends on matching the right active to the right patient. A dedicated dermatological range is available for clinicians and patients, and our formulation desk answers questions on literature, access and formulation over WhatsApp.

A dedicated dermatological range dispensing Cetosome®-powered formulations is available from Monoskin (monoskin.com). Clinicians can request the literature dossier and formulation details from the desk.

References

  1. Feldmann RJ, Maibach HI. Regional Variation in Percutaneous Penetration of 14C Cortisol in Man. Journal of Investigative Dermatology 48(2):181–183. 1967.DOI 10.1038/jid.1967.29
  2. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 9(3):165–169. 2000.DOI 10.1034/j.1600-0625.2000.009003165.x
  3. Elias PM. Stratum Corneum Defensive Functions: An Integrated View. Journal of Investigative Dermatology 125(2):183–200. 2005.DOI 10.1111/j.0022-202X.2005.23668.x
  4. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
  5. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes. US Patent US 8,394,759 B2. 2013.Priority 21 Nov 2008; filed 29 Oct 2009; granted 12 Mar 2013. Foundational cetylated-fatty-ester penetrant work, incorporated by reference into US 9,084,818 B2.
  6. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. International Journal of Pharmaceutics 332(1–2):1–16. 2007.DOI 10.1016/j.ijpharm.2006.12.005
  7. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes — novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Journal of Controlled Release 65(3):403–418. 2000.DOI 10.1016/S0168-3659(99)00222-9
  8. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochimica et Biophysica Acta — Biomembranes 1104(1):226–232. 1992.DOI 10.1016/0005-2736(92)90154-E
  9. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. International Journal of Pharmaceutics 172(1–2):33–70. 1998.DOI 10.1016/S0378-5173(98)00169-0
  10. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles. Journal of Extracellular Vesicles 7(1):1535750. 2018.DOI 10.1080/20013078.2018.1535750
  11. US Food and Drug Administration, Center for Biologics Evaluation and Research. Public Safety Notification on Exosome Products. FDA Safety & Availability (Biologics). 2019.
  12. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery — a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics 50(1):161–177. 2000.DOI 10.1016/S0939-6411(00)00087-4
  13. Sattur S, Talathi A, Shetty G, Arsiwala S, Pereira R, Dhoot D. Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men. Cureus 15(10):e46568. 2023.DOI 10.7759/cureus.46568 · PMID 37937040 · PMC10626207Randomised, open-label, 5 centres; 80 enrolled, 40 analysed. One author employed by the product's marketing company.
  14. Kerure A, Ghalla M, Mahajan S, Dhoot D, Barkate H. Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus 15(7):e41681. 2023.DOI 10.7759/cureus.41681 · PMID 37575862 · PMC10413304Retrospective, 66 centres, n = 261. Industry-affiliated authors (employees of the product's marketing company).
  15. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology 74(5):945–973.e33. 2016.DOI 10.1016/j.jaad.2015.12.037

Methodology

Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.

Conflict of interest & scope

Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.

In your routine or your clinic

Explore Cetosome® formulations

Cetosome® vehicles are dispensed through dermatology, not mass retail. The direct way to bring the technology into your routine or practice is Monoskin, the dermatological range built on the platform.

For your skin: choose a need

For your clinic

Stocking or prescribing Cetosome® formulations? Reach the clinic team, or ask our formulation desk for the literature dossier.

Opens monoskin.com in a new tab. Diagnosis and the choice of active belong to your dermatologist.